Adverse effects of golimumab in the treatment of rheumatologic diseases

Bibliography

• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor; antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007;11:1369-84
   PubMed Web of Science ®Google Scholar
• Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factoralpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol. Hepatol 2006;3:220-8
   PubMedGoogle Scholar
• Feldmann M, Brennan FM, Williams RO, et al. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of: anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004;18:59-8
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011;10:563-8
   PubMed Web of Science ®Google Scholar
• Zidi I, Bouaziz A, Mnif W, et al. Golimumab therapy of rheumatoid arthritis: an overview. Scand J Immunol 2010;72:75-85
   PubMed Web of Science ®Google Scholar
• Food and Drug Adminstration. Simponi (golimumab). Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProductsucm162802.htm 2011. Ref Type: Generic
   Google Scholar
• Xu ZH, Lee H, Vu T, et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther 2010;48:596-607
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network; meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
   Google Scholar
• Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25(4):549-67
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54(8):2368-76
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011
   Google Scholar
• Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52(11):3403-12
   PubMed Web of Science ®Google Scholar
• Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002;65:33-8
   PubMedGoogle Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in thefirst 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50(1):124-31
   PubMed Web of Science ®Google Scholar
• Jain A, Singh JA. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 2013;5(3):265-99
   PubMed Web of Science ®Google Scholar
• Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65(3):353-61
   PubMed Web of Science ®Google Scholar
• Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72(2):229-34
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309(9):887-95
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012;64(10):1480-9
   PubMed Web of Science ®Google Scholar
• Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010;25:1-17
   PubMedGoogle Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Landewé RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71(10):1671-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012;39(6):1185-91
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Hall S, et al. Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: results Through 2 Years of the GO-FORWARD Study Extension. J Rheumatol 2013;40(7):1097-103
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75
   PubMed Web of Science ®Google Scholar
• Simsek I, Yazici Y. Safety and clinical efficacy of golimumab in the treatment of arthritides. Drug Healthc Patient Saf 2010;2:169-80
   PubMedGoogle Scholar
• Food and Drug Administration. SIMPONI full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s006lbl.pdf 2009. 2011. Ref Type: Generic
   Google Scholar
• Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res (Hoboken) 2013;65(2):309-13
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. 2009. Ann Rheum Dis 2010;69(Suppl):i2-29
   Google Scholar
• Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119(5):1167-77
   PubMed Web of Science ®Google Scholar
• Whintrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10
   PubMedGoogle Scholar
• Jain A, Singh JA. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 2013;5(3):265-99
   PubMed Web of Science ®Google Scholar
• Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population. J Crohns Colitis 2013; pii: S1873-9946(13)00108-6
   Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2012; [Epub ahead of print]
   Google Scholar
• van der Heijde D, Braun J, Deodhar A, et al. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology (Oxford) 2013;52(2):321-5
   PubMed Web of Science ®Google Scholar
• Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009;161:797-80
   PubMed Web of Science ®Google Scholar
• Martin J, Walsh C, Gibbs A, et al. Comparison of interferon (gamma) release assays and conventional screening tests before tumour necrosis factor (alpha) blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5
   PubMed Web of Science ®Google Scholar
• Hsia EC, Schluger N, Cush JJ, et al. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64(7):2068-77
   PubMed Web of Science ®Google Scholar
• Murakami S, Takeno M, Kirino Y, et al. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis 2009;89:136-41
   PubMed Web of Science ®Google Scholar
• Park JH, Seo GY, Lee JS, et al. Positive conversion of detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63
   PubMed Web of Science ®Google Scholar
• Soborg B, Ruhwald M, Hetland ML, et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009;36:1876-84
   PubMed Web of Science ®Google Scholar
• Casas S, Andreu A, Juanola X, et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-γ release assay in patients considered for anti-tumor necrosis factor-alpha therapy. Diagn Microbiol Infect Dis 2011;71:57-65
   PubMed Web of Science ®Google Scholar
• Kwakernaak AJ, Houtman PM, Weel JF, et al. A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor alpha inhibitor. Clin Rheumatol 2011;30:505-10
   PubMed Web of Science ®Google Scholar
• Lange B, Vavra M, Kern WV, Wagner D. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int J Tuberc Lung Dis 2012;16:492-5
   PubMed Web of Science ®Google Scholar
• Mínguez S, Latorre I, Mateo L, et al. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 2012;31:785-94
   PubMed Web of Science ®Google Scholar
• Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection: Performance of tuberculin skin test and interferon-gamma release assays under real-life conditions. Ann Rheum Dis 2012;71:1791-5
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Tsikrika S, Hatzara C, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18(12):2102-8
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need. Ann Rheum Dis 2012;71(11):1757-60
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee SW, Chung WT, et al. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 2011;31:271-8
   PubMed Web of Science ®Google Scholar
• Garcovich S, Ruggeri A, D’Agostino M, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2011;29:790-4
   PubMed Web of Science ®Google Scholar
• Scrivo R, Sauzullo I, Mengoni F, et al. Mycobacterial interferon-gamma release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 2013;40(2):157-65
   PubMed Web of Science ®Google Scholar
• Chen DY, Shen GH, Chen YM, et al. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF (alpha) inhibitors: the utility of IFN (gamma) assay. Ann Rheum Dis 2012;71:231-7
   PubMed Web of Science ®Google Scholar
• Lin MV, Blonski W, Buchner AM, et al. The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2013;58(4):1149-56
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8(6):348-57
   PubMed Web of Science ®Google Scholar
• Viganò M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012;12(2):193-207
   PubMed Web of Science ®Google Scholar
• Cabrera Villalba SR, Victoria Hernández Miguel M, Sanmartí Sala R. How does one manage patients with rheumatoid arthritis and positive serology to hepatitis B, hepatitis C, human immunodeficiency virus? Reumatol Clin 2011;7(3):203-7
   Google Scholar
• Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011;50(9):1700-11
   PubMed Web of Science ®Google Scholar
• Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol 2010;23(3):965-9
   PubMed Web of Science ®Google Scholar
• Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009;28(7):787-91
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008;8(2):100-3
   PubMed Web of Science ®Google Scholar
• Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008;27(8):1069-71
   PubMed Web of Science ®Google Scholar
• Paradisi A, Caldarola G, Capizzi R, Siciliano M. Annichiarico E,Vecchio FM, et al. Safety of etanercept in patients with pso-riasis and hepatitis C virus assessed by liver histopathology:preliminary data. J Am Acad Dermatol 2010;62:1067-9
   PubMed Web of Science ®Google Scholar
• Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35(3):421-4
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011;90(6):359-71
   PubMed Web of Science ®Google Scholar
• Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010;29(9):1021-9
   PubMed Web of Science ®Google Scholar
• Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:1612-17
   PubMed Web of Science ®Google Scholar
• Armengot-Carbó M, Velasco M, Giner R, Gimeno E. Acute hepatitis C in a patient receiving etanercept. Actas Dermosifiliogr 2013;104(3):239-41
   PubMedGoogle Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(9):2757-64
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 2007;56(9):2886-95
   PubMed Web of Science ®Google Scholar
• Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20(2):119-30
   PubMed Web of Science ®Google Scholar
• Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70(11):1895-904
   PubMed Web of Science ®Google Scholar
• Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 2009;22:418-30
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladström A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may ba associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54(3):692-701
   PubMed Web of Science ®Google Scholar
• Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60(11):3180-9
   PubMed Web of Science ®Google Scholar
• Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011;38(8):1552-62
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308(9):898-908
   PubMed Web of Science ®Google Scholar
• Moulis G, Sommet A, Béné J, et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One 2012;7(11):e48991
   PubMed Web of Science ®Google Scholar
• Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with TNF-inhibitors in RA: a review of their methodologies and results. Arthritis Rheum 2012;64:21-32
   PubMed Web of Science ®Google Scholar
• Moulis G, Sommet A, Lapeyre-Mestre M. Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard et al. Arthritis Rheum 2013;65(6):1670-1
   PubMed Web of Science ®Google Scholar
• LE Blay P, Mouterde G, Barnetche T, et al. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol 2012;39(4):712-15
   PubMed Web of Science ®Google Scholar
• Zidi I, Bouaziz A, Mnif W, et al. Golimumab and malignancies: true or false association? Med Oncol 2011;28(2):641-8
   PubMed Web of Science ®Google Scholar
• Chovel-Sella A, Karplus R, Sella T, Amital H. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis. Isr Med Assoc J 2012;14(6):390-4
   PubMed Web of Science ®Google Scholar
• Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohns Colitis 2013; pii: S1873-9946(13)00029-9
   Web of Science ®Google Scholar
• Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009;58(8):1033-9
   PubMed Web of Science ®Google Scholar
• Bonnet N, Guis S, Koeppel MC, et al. Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases. Ann Dermatol Venereol 2010;137(1):12-20
   PubMed Web of Science ®Google Scholar
• Nagy G, Lukács K, Sziray A, et al. Adverse events during biological therapy – focusing on dermatological side-effects. Orv Hetil 2011;152(6):212-20
   PubMedGoogle Scholar
• Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76
   PubMed Web of Science ®Google Scholar
• Lee HH, Song IH, Friedrich M, et al. Cutaneous side effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486-91
   PubMed Web of Science ®Google Scholar
• Fidder H, chnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
   PubMed Web of Science ®Google Scholar
• Llao J, Gomez-Pastrana B, Gordillo J, et al. Skin lesions in patients with inflammatory bowel disease treated with immunomodulators and/or anti-tumor necrosis factor. J Crohns Colitis 2011;P223 5:106
   Google Scholar
• Zidi I, Bartegi A, Ben AN. Dermatologic adverse events: golimumab, friend or foe? Pharmazie 2011;66(1):5-10
   PubMed Web of Science ®Google Scholar
• Saleem G, Li SC, MacPherson BR, et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001;44:1966-8
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Gilmer K. No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis. Ann Rheum Dis 2004;63:199
   Web of Science ®Google Scholar
• Ierardi E, Della Valle N, Nacchiero MC, et al. Infliximab single administration followed by acute liver injury. Inflamm Bowel Dis 2006;12:1089-91
   PubMed Web of Science ®Google Scholar
• Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6
   PubMed Web of Science ®Google Scholar
• Moum B, Konopski Z, Tufteland KF, et al. Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 2007;13:1584-6
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Cañas C, Jaller JJ, et al. Serious liver disease induced by infl iximab. Clin Rheumatol 2007;26:578-81
   PubMed Web of Science ®Google Scholar
• Farah M, Al Rashidi A, Owen DA, et al. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 2008;35:349-51
   PubMed Web of Science ®Google Scholar
• Thiéfin G, Morelet A, Heurgué A, et al. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008;75:737-9
   PubMed Web of Science ®Google Scholar
• Remicade. Summary of product characteristics (SPC). Centocor, Malvern; Pennsylvania, USA: 2007
   Google Scholar
• Enbrel package insert. Amgen Corp; Thousand Oaks, California, USA: 2006
   Google Scholar
• HUMIRA. Abbott Laboratories; North Chicago, Illinois, USA: 2007
   Google Scholar
• Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69(9):1612-17
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Bingham CO III, delsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013;72(3):381-9
   PubMed Web of Science ®Google Scholar
• Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62(4):917-28; Erratum in: Arthritis Rheum. 2010 Oct;62(10):3130
   PubMed Web of Science ®Google Scholar
• Combe B, Dasgupta B, Louw I, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9(3):164-72
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013;12(7):703-8
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72(2):165-78
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1445-52
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9
   PubMed Web of Science ®Google Scholar
• Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-αbiopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46:1828-34
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or dalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70:284-8
   PubMed Web of Science ®Google Scholar
• van De Putte L B, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
   PubMed Web of Science ®Google Scholar
• Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008;18:252-62
   PubMed Web of Science ®Google Scholar
• Petitpain N, Ambier N, Wahl D, et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000–2006. Biomed Mater Eng 2009;355-64
   PubMed Web of Science ®Google Scholar
• Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Rep 2010;4:12
   Google Scholar
• Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;63:877-83
   PubMed Web of Science ®Google Scholar
• Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41:1133-7
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-αmonoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96
   PubMed Web of Science ®Google Scholar
• Zidi I, Bouaziz A, Ben Amor N. Golimumab and immunogenicity? 2010 and beyond. Pharmazie 2011;66(4):233-43
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
   PubMed Web of Science ®Google Scholar